{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T15:00:21.783902",
  "document": "02_Article_AAV Management Guidelines.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/02_Article_AAV Management Guidelines.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 15,
  "total_validated": 15,
  "total_rejected": 0,
  "genes": [
    {
      "matched_text": "MAL",
      "hgnc_symbol": "MAL",
      "full_name": "mal, T cell differentiation protein (MAL blood group)",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6817",
        "entrez": "4118",
        "ensembl": "ENSG00000172005",
        "uniprot": "P21145",
        "omim": "188860"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6817",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "4118",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000172005",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "188860",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P21145",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "280270",
          "disease_name": "Pelizaeus-Merzbacher-like disease",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "for Research & Evaluation recommendations,* where applicable (see online supplemental file 1 for a full description of methods). The task force consisted of 20 clinical experts including rheumatologists (MCC, BH, JH, OK, RAL, AJM, CBM, JM, PM, GT, DV), internists (AM, DB, BT) and nephrologists (AK, MAL, MS, YKOT, AV, DJ), from 15 European countries and the USA (PM), 2 methodologists (RAL; GT), convenor (BH) and co-convenor (DJ), 2 delegates of the EULAR young rheumatologists’ network EMEUNET (AB, SM), 2 fellows (BS-A, JHS), 1 health professional (NH) and 2 patient representatives (PV, FP-K).\n\n®",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ]
    },
    {
      "matched_text": "CD19",
      "hgnc_symbol": "CD19",
      "full_name": "CD19 molecule",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "1633",
        "entrez": "930",
        "ensembl": "ENSG00000177455",
        "uniprot": "P15391",
        "omim": "107265"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "1633",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "930",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000177455",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "107265",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P15391",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "696881",
          "disease_name": "Common variable immunodeficiency phenotype due to CD19/CD81 deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "of remission of relapsing EGPA after induction of remission for non-organthreatening or life-threatening manifestations at the time of relapse, we recommend treatment with mepolizumab.* In the management of patients with AAV, we recommend that structured clinical assessment, rather than ANCA and/or CD19+ B cell testing alone, should inform decisions on changes in 1b*\n\ntreatment.\n\n9.341.1\n\nContinued\n\nTable 3 Continued\n\nLoE SoR FV (%) LoA (0-10) 16 In patients with AAV receiving rituximab, we recommend measurement of serum 1b B 100 9.241.4 immunoglobulin concentrations prior to each course of rituxi",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "atic",
      "hgnc_symbol": "ATIC",
      "full_name": "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "794",
        "entrez": "471",
        "ensembl": "ENSG00000138363",
        "uniprot": "P31939",
        "omim": "601731"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "794",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "471",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000138363",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "601731",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P31939",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "250977",
          "disease_name": "AICA-ribosiduria",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "lves multiple organs and relapses are frequent, a structured clinical assessment during follow-up at regular intervals is recommended. The BVAS'®” has been used in different variants in the majority of RCTs in AAV and can be helpful in clinical practice to document response to treatment in a system-atic fashion. Damage resulting from AAV or its treatment needs to be distinguished from active disease to avoid unnecessarily escalating treatment. The Vasculitis Damage Index'”® is a validated instrument to record damage in AAV and provides definitions that help distinguish damage from active disease.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "NHS",
      "hgnc_symbol": "NHS",
      "full_name": "NHS actin remodeling regulator",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "7820",
        "entrez": "4810",
        "ensembl": "ENSG00000188158",
        "uniprot": "Q6T4R5",
        "omim": "300457"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "7820",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "4810",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000188158",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "300457",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q6T4R5",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "627",
          "disease_name": "Nance-Horan syndrome",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "98991",
          "disease_name": "Early-onset nuclear cataract",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "98994",
          "disease_name": "Total early-onset cataract",
          "association_type": "Candidate gene tested in"
        }
      ],
      "context": "of Rheumatology, Skane Hospital, Lund, Sweden \"Department of Internal Medicine and Therapeutics, Universita di Pavia, Pavia, Italy 'SDivision of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy \"Vasculitis Service, Rheumatology Department, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK *°2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland *'Division of Nephrology, Department of Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Eng",
      "hgnc_symbol": "ENG",
      "full_name": "endoglin",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "3349",
        "entrez": "2022",
        "ensembl": "ENSG00000106991",
        "uniprot": "P17813",
        "omim": "131195"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "3349",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "2022",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000106991",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "131195",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P17813",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "774",
          "disease_name": "Hereditary hemorrhagic telangiectasia",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "275777",
          "disease_name": "Heritable pulmonary arterial hypertension",
          "association_type": "Candidate gene tested in"
        },
        {
          "orphacode": "231160",
          "disease_name": "Familial cerebral saccular aneurysm",
          "association_type": "Major susceptibility factor in"
        },
        {
          "orphacode": "329971",
          "disease_name": "Generalized juvenile polyposis/juvenile polyposis coli",
          "association_type": "Candidate gene tested in"
        }
      ],
      "context": "d to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.\n\n19 Jayne DRW, Merkel PA, Schall TJ, et a/. Avacopan for the treatment of ANCA-associated vasculitis. N Eng! J Med 2021;384:599-609.\n\n20 Smith RM, Jones RB, Specks U, ef a/. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020;79:1243-9.\n\n21. Jones RB, Hiemstra TF, Ballarin J, et a/. Mycophenolate mofetil versus cyclophosphamide for remission induction",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "iDs",
      "hgnc_symbol": "IDS",
      "full_name": "iduronate 2-sulfatase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "5389",
        "entrez": "3423",
        "ensembl": "ENSG00000010404",
        "uniprot": "P22304",
        "omim": "300823"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "5389",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3423",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000010404",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "300823",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P22304",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "217093",
          "disease_name": "Mucopolysaccharidosis type 2, attenuated form",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "217085",
          "disease_name": "Mucopolysaccharidosis type 2, severe form",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "e management of large vessel vasculitis. Ann Rheum Dis 2020;79:19-30.\n\n23 Smolen JS, Landewé RBM, Bergstra SA, et a/. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3-18.\n\nORCID iDs\n\nBernhard Hellmich http://orcid.org/0000-0002-8014-1801 Alvise Berti http://orcid.org/0000-0002-7831-921X Maria C Cid http://orcid.org/0000-0002-4730-0938 Peter A Merkel http://orcid.org/0000-0001-9284-7345 Aladdin J Mohammad http://orcid.org/0000-0002-7 169-6936\n\n24 Ramiro S, Nikiphorou E, Seprian",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "TF",
      "hgnc_symbol": "TF",
      "full_name": "transferrin",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "11740",
        "entrez": "7018",
        "ensembl": "ENSG00000091513",
        "uniprot": "P02787",
        "omim": "190000"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "11740",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "7018",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000091513",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "190000",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P02787",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "1195",
          "disease_name": "Congenital atransferrinemia",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "x9} 0} payejas sasn 410} Bulpnyout ‘}yHiuAdoo Aq pa}0e}01q\n\n108 Chanouzas D, McGregor JAG, Nightingale P, et a/. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephro! 2019;20:58.\n\nLyons PA, Rayner TF, Trivedi S, et a/. Genetically distinct subsets within ANCA-associated vasculitis. N Eng/ J Med 2012;367:214-23.\n\n80 Csernok E, Hellmich B. Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 2020;19:102514.\n\n109 Waki D, Nishimura K, Tokumasu H, et a/. Initial",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Proc",
      "hgnc_symbol": "PROC",
      "full_name": "protein C, inactivator of coagulation factors Va and VIIIa",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "9451",
        "entrez": "5624",
        "ensembl": "ENSG00000115718",
        "uniprot": "P04070",
        "omim": "612283"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "9451",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "5624",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000115718",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "612283",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P04070",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "745",
          "disease_name": "Severe hereditary thrombophilia due to congenital protein C deficiency",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One 2015;10:e0126016.\n\n117 Rifle G, Chalopin JM, Zech P, et a/. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study. Proc Eur Dial Transplant Assoc 1981;18:493-502.\n\n91 van Daalen EE, Rizzo R, Kronbichler A, et a/. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 2017;76:1064-9.\n\n92. Bénard V, Farhat C, Zarandi-Nowroozi M, et a/. Comparison of two rituximab induction re",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "GK",
      "hgnc_symbol": "GK",
      "full_name": "glycerol kinase",
      "confidence": 0.85,
      "is_alias": false,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "4289",
        "entrez": "2710",
        "ensembl": "ENSG00000198814",
        "uniprot": "P32189",
        "omim": "300474"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "4289",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "2710",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000198814",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "300474",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P32189",
          "display": null
        }
      ],
      "associated_diseases": [
        {
          "orphacode": "284414",
          "disease_name": "Glycerol kinase deficiency, adult form",
          "association_type": "Disease-causing germline mutation(s) in"
        },
        {
          "orphacode": "284411",
          "disease_name": "Glycerol kinase deficiency, juvenile form",
          "association_type": "Disease-causing germline mutation(s) in"
        }
      ],
      "context": "t patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39-52.\n\n193 Maritati F Alberici F, Oliva E, et a/. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial. PLoS One 2017;12:e0185880.\n\n216 Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76:476-85.\n\n194 Watanabe H, Sada K-E, Matsumoto Y,",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "task",
      "hgnc_symbol": "KCNK3",
      "full_name": "potassium two pore domain channel subfamily K member 3",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "6278",
        "entrez": "3777",
        "ensembl": "ENSG00000171303",
        "uniprot": "O14649",
        "omim": "603220"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "6278",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "3777",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000171303",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "603220",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "O14649",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "that have the potential to change clinical care and support the need for an update.\n\n> Additional supplemental material is published online only. To view, please visit the journal online (http://dx. doi.org/10.1136/ard-2022- 223764).\n\nMethods Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries. We modified existing recommendations and created new recommendations. Results Four overarching principles and 17 recommendations were formulated. We recommend biopsies and ANCA testing to assist in",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "bars",
      "hgnc_symbol": "CTBP1",
      "full_name": "C-terminal binding protein 1",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "2494",
        "entrez": "1487",
        "ensembl": "ENSG00000159692",
        "uniprot": "Q13363",
        "omim": "602618"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "2494",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "1487",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000159692",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "602618",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q13363",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "and whether avacopan can be stopped when RTX is given for maintenance of remission.\n\nFigure 2 Protocol target glucocorticoid (GC) doses in AAV induction trials®' 1° \"321-226 (black line), illustrating how these compare with the reduced GC group from the PEXIVAS trial (red line). The line and error bars represent the mean and 95% Cls across a range of weights, genders and ages. AAV, antineutrophil cytoplasmic antibody-associated vasculitis.\n\n7. PLEX may be considered as part of therapy to induce remission in GPA or MPA for those with a serum creatinine >300umol/L due to active glomerulonephritis.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "arms",
      "hgnc_symbol": "KIDINS220",
      "full_name": "kinase D interacting substrate 220",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "29508",
        "entrez": "57498",
        "ensembl": "ENSG00000134313",
        "uniprot": "Q9ULH0",
        "omim": "615759"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "29508",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "57498",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000134313",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "615759",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q9ULH0",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "? A single-centre prospective randomised trial compared oral CYC with MTX for lyear after remission induction with CYC in different subtypes of AAV.'” In the subgroup of 30 patients with EGPA who had either an FFS >1 or peripheral neuropathy, no difference in relapse rates between the two treatment arms was observed. Although no excess in adverse events was found in this study, we do not recommend CYC for remission maintenance in view of its toxicity. However, this study provides a rationale for use of MTX for maintenance of remission in EGPA, although the small sample size of patients with EGPA p",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "era",
      "hgnc_symbol": "ESR1",
      "full_name": "estrogen receptor 1",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "3467",
        "entrez": "2099",
        "ensembl": "ENSG00000091831",
        "uniprot": "P03372",
        "omim": "133430"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "3467",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "2099",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000091831",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "133430",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "P03372",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephro! 2019;20:58.\n\nLyons PA, Rayner TF, Trivedi S, et a/. Genetically distinct subsets within ANCA-associated vasculitis. N Eng/ J Med 2012;367:214-23.\n\n80 Csernok E, Hellmich B. Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 2020;19:102514.\n\n109 Waki D, Nishimura K, Tokumasu H, et a/. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retr",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "Rifle",
      "hgnc_symbol": "LRSAM1",
      "full_name": "leucine rich repeat and sterile alpha motif containing 1",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "25135",
        "entrez": "90678",
        "ensembl": "ENSG00000148356",
        "uniprot": "Q6UWE0",
        "omim": "610933"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "25135",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "90678",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000148356",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "610933",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q6UWE0",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011;57:566-74.\n\n90 Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One 2015;10:e0126016.\n\n117 Rifle G, Chalopin JM, Zech P, et a/. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study. Proc Eur Dial Transplant Assoc 1981;18:493-502.\n\n91 van Daalen EE, Rizzo R, Kronbichler A, et a/. Effect of rituximab on malignancy ri",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    },
    {
      "matched_text": "SARS",
      "hgnc_symbol": "SARS2",
      "full_name": "seryl-tRNA synthetase 2, mitochondrial",
      "confidence": 0.8,
      "is_alias": true,
      "locus_type": "gene with protein product",
      "chromosome": null,
      "codes": {
        "hgnc_id": "17697",
        "entrez": "54938",
        "ensembl": "ENSG00000104835",
        "uniprot": "Q9NP81",
        "omim": "612804"
      },
      "all_identifiers": [
        {
          "system": "HGNC",
          "code": "17697",
          "display": null
        },
        {
          "system": "ENTREZ",
          "code": "54938",
          "display": null
        },
        {
          "system": "ENSEMBL",
          "code": "ENSG00000104835",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "612804",
          "display": null
        },
        {
          "system": "UNIPROT",
          "code": "Q9NP81",
          "display": null
        }
      ],
      "associated_diseases": [],
      "context": "UVAS meeting and EUVAS education forum. Autoimmun Rev 2021;20:102986.\n\n168 Harper L, Morgan MD, Walsh M, et a/. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012;71:955-60.\n\n143 Mrak D, Tobudic S, Koblischke M. SARS-cov-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cellmediated immunity. Ann Rheum Dis 2021;80:1345-50.\n\npapeojuMoOg eyep pue\n\n169 Hogan SL, Falk RJ, Chin H, et a/. Predictors of relapse and treatment resistance in antineutrophil cytoplas",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_orphadata_genes.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ]
    }
  ]
}